JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194218, encodeId=432a2194218a4, content=偏重的研究方向：临床肿瘤基础研究 经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230522/2d526ad49c9d4a238ea5253f6b93381d/a6944e09a4254363923c04ea9167b795.jpg, createdBy=e0d95253850, createdName=lmzzzh, createdTime=Wed Mar 20 09:43:23 CST 2024, time=2024-03-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2191575, encodeId=455e21915e55e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基础研究 经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:47:39 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2185219, encodeId=922b218521981, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Feb 01 14:16:21 CST 2024, time=2024-02-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183905, encodeId=34682183905f8, content=偏重的研究方向：肿瘤 经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Jan 25 16:12:06 CST 2024, time=2024-01-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1237643, encodeId=3dfd123e643cd, content=审稿速度:1.0 偏重的研究方向：胃癌;生信 经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Aug 09 17:19:39 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160993, encodeId=8fa32160993d6, content=有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Oct 05 08:02:49 CST 2023, time=2023-10-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2174798, encodeId=c25321e4798cc, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信加细胞功能实验 经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！ Submission is in publishing and rights 12 Dec 2023 Peer review Submission status Date Submission accepted 12 Dec 2023 Submission under peer review 06 Dec 2023 Submission passed technical check 06 Dec 2023 Revision received 03 Dec 2023 Submission under peer review 15 Nov 2023 Submission passed technical check 15 Nov 2023 Revision received 14 Nov 2023 Submission under peer review 05 Sep 2023 Submission passed technical check 05 Sep 2023 Revision received 04 Sep 2023 Submission under peer review 05 Aug 2023 Technical check Submission status Date Submission passed technical check 05 Aug 2023 Submission is under technical check 04 Aug 2023 Submission received Submission status Date Submission received 04 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=究极奥美拉唑, createdTime=Wed Dec 13 20:39:35 CST 2023, time=2023-12-13, status=1, ipAttribution=广西)]

2024-03-06 ms5000001486959246 来自北京

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：还是比较快的
Submission is in publishing and rights
05 Mar 2024
Peer review
Submission status Date
Submission accepted
05 Mar 2024
Submission under peer review
16 Feb 2024
Submission passed technical check
16 Feb 2024
Revision received
15 Feb 2024
Submission under peer review
11 Jan 2024
Technical check
Submission status Date
Submission passed technical check
11 Jan 2024
Submission is under technical check
10 Jan 2024
Submission received
Submission status Date
Submission received
10 Jan 2024

26 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194218, encodeId=432a2194218a4, content=偏重的研究方向：临床肿瘤基础研究 经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230522/2d526ad49c9d4a238ea5253f6b93381d/a6944e09a4254363923c04ea9167b795.jpg, createdBy=e0d95253850, createdName=lmzzzh, createdTime=Wed Mar 20 09:43:23 CST 2024, time=2024-03-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2191575, encodeId=455e21915e55e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基础研究 经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:47:39 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2185219, encodeId=922b218521981, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Feb 01 14:16:21 CST 2024, time=2024-02-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183905, encodeId=34682183905f8, content=偏重的研究方向：肿瘤 经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Jan 25 16:12:06 CST 2024, time=2024-01-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1237643, encodeId=3dfd123e643cd, content=审稿速度:1.0 偏重的研究方向：胃癌;生信 经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Aug 09 17:19:39 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160993, encodeId=8fa32160993d6, content=有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Oct 05 08:02:49 CST 2023, time=2023-10-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2174798, encodeId=c25321e4798cc, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信加细胞功能实验 经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！ Submission is in publishing and rights 12 Dec 2023 Peer review Submission status Date Submission accepted 12 Dec 2023 Submission under peer review 06 Dec 2023 Submission passed technical check 06 Dec 2023 Revision received 03 Dec 2023 Submission under peer review 15 Nov 2023 Submission passed technical check 15 Nov 2023 Revision received 14 Nov 2023 Submission under peer review 05 Sep 2023 Submission passed technical check 05 Sep 2023 Revision received 04 Sep 2023 Submission under peer review 05 Aug 2023 Technical check Submission status Date Submission passed technical check 05 Aug 2023 Submission is under technical check 04 Aug 2023 Submission received Submission status Date Submission received 04 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=究极奥美拉唑, createdTime=Wed Dec 13 20:39:35 CST 2023, time=2023-12-13, status=1, ipAttribution=广西)]

2024-03-13 ms9000000002911795 来自黑龙江省

偏重的研究方向：肿瘤临床;肿瘤
经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了

17 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194218, encodeId=432a2194218a4, content=偏重的研究方向：临床肿瘤基础研究 经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230522/2d526ad49c9d4a238ea5253f6b93381d/a6944e09a4254363923c04ea9167b795.jpg, createdBy=e0d95253850, createdName=lmzzzh, createdTime=Wed Mar 20 09:43:23 CST 2024, time=2024-03-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2191575, encodeId=455e21915e55e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基础研究 经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:47:39 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2185219, encodeId=922b218521981, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Feb 01 14:16:21 CST 2024, time=2024-02-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183905, encodeId=34682183905f8, content=偏重的研究方向：肿瘤 经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Jan 25 16:12:06 CST 2024, time=2024-01-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1237643, encodeId=3dfd123e643cd, content=审稿速度:1.0 偏重的研究方向：胃癌;生信 经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Aug 09 17:19:39 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160993, encodeId=8fa32160993d6, content=有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Oct 05 08:02:49 CST 2023, time=2023-10-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2174798, encodeId=c25321e4798cc, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信加细胞功能实验 经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！ Submission is in publishing and rights 12 Dec 2023 Peer review Submission status Date Submission accepted 12 Dec 2023 Submission under peer review 06 Dec 2023 Submission passed technical check 06 Dec 2023 Revision received 03 Dec 2023 Submission under peer review 15 Nov 2023 Submission passed technical check 15 Nov 2023 Revision received 14 Nov 2023 Submission under peer review 05 Sep 2023 Submission passed technical check 05 Sep 2023 Revision received 04 Sep 2023 Submission under peer review 05 Aug 2023 Technical check Submission status Date Submission passed technical check 05 Aug 2023 Submission is under technical check 04 Aug 2023 Submission received Submission status Date Submission received 04 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=究极奥美拉唑, createdTime=Wed Dec 13 20:39:35 CST 2023, time=2023-12-13, status=1, ipAttribution=广西)]

2023-05-13 wwei0125 来自山东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志

67 25

展开25条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194218, encodeId=432a2194218a4, content=偏重的研究方向：临床肿瘤基础研究 经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230522/2d526ad49c9d4a238ea5253f6b93381d/a6944e09a4254363923c04ea9167b795.jpg, createdBy=e0d95253850, createdName=lmzzzh, createdTime=Wed Mar 20 09:43:23 CST 2024, time=2024-03-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2191575, encodeId=455e21915e55e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基础研究 经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:47:39 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2185219, encodeId=922b218521981, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Feb 01 14:16:21 CST 2024, time=2024-02-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183905, encodeId=34682183905f8, content=偏重的研究方向：肿瘤 经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Jan 25 16:12:06 CST 2024, time=2024-01-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1237643, encodeId=3dfd123e643cd, content=审稿速度:1.0 偏重的研究方向：胃癌;生信 经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Aug 09 17:19:39 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160993, encodeId=8fa32160993d6, content=有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Oct 05 08:02:49 CST 2023, time=2023-10-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2174798, encodeId=c25321e4798cc, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信加细胞功能实验 经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！ Submission is in publishing and rights 12 Dec 2023 Peer review Submission status Date Submission accepted 12 Dec 2023 Submission under peer review 06 Dec 2023 Submission passed technical check 06 Dec 2023 Revision received 03 Dec 2023 Submission under peer review 15 Nov 2023 Submission passed technical check 15 Nov 2023 Revision received 14 Nov 2023 Submission under peer review 05 Sep 2023 Submission passed technical check 05 Sep 2023 Revision received 04 Sep 2023 Submission under peer review 05 Aug 2023 Technical check Submission status Date Submission passed technical check 05 Aug 2023 Submission is under technical check 04 Aug 2023 Submission received Submission status Date Submission received 04 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=究极奥美拉唑, createdTime=Wed Dec 13 20:39:35 CST 2023, time=2023-12-13, status=1, ipAttribution=广西)]

2024-03-20 lmzzzh 来自河南省

偏重的研究方向：临床肿瘤基础研究
经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收

16 0

[GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194218, encodeId=432a2194218a4, content=偏重的研究方向：临床肿瘤基础研究 经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230522/2d526ad49c9d4a238ea5253f6b93381d/a6944e09a4254363923c04ea9167b795.jpg, createdBy=e0d95253850, createdName=lmzzzh, createdTime=Wed Mar 20 09:43:23 CST 2024, time=2024-03-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2191575, encodeId=455e21915e55e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基础研究 经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:47:39 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2185219, encodeId=922b218521981, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Feb 01 14:16:21 CST 2024, time=2024-02-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183905, encodeId=34682183905f8, content=偏重的研究方向：肿瘤 经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Jan 25 16:12:06 CST 2024, time=2024-01-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1237643, encodeId=3dfd123e643cd, content=审稿速度:1.0 偏重的研究方向：胃癌;生信 经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Aug 09 17:19:39 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160993, encodeId=8fa32160993d6, content=有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Oct 05 08:02:49 CST 2023, time=2023-10-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2174798, encodeId=c25321e4798cc, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信加细胞功能实验 经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！ Submission is in publishing and rights 12 Dec 2023 Peer review Submission status Date Submission accepted 12 Dec 2023 Submission under peer review 06 Dec 2023 Submission passed technical check 06 Dec 2023 Revision received 03 Dec 2023 Submission under peer review 15 Nov 2023 Submission passed technical check 15 Nov 2023 Revision received 14 Nov 2023 Submission under peer review 05 Sep 2023 Submission passed technical check 05 Sep 2023 Revision received 04 Sep 2023 Submission under peer review 05 Aug 2023 Technical check Submission status Date Submission passed technical check 05 Aug 2023 Submission is under technical check 04 Aug 2023 Submission received Submission status Date Submission received 04 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=究极奥美拉唑, createdTime=Wed Dec 13 20:39:35 CST 2023, time=2023-12-13, status=1, ipAttribution=广西)]

2024-03-06 ms8000000280791103 来自重庆

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤;基础研究
经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊

15 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194218, encodeId=432a2194218a4, content=偏重的研究方向：临床肿瘤基础研究 经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230522/2d526ad49c9d4a238ea5253f6b93381d/a6944e09a4254363923c04ea9167b795.jpg, createdBy=e0d95253850, createdName=lmzzzh, createdTime=Wed Mar 20 09:43:23 CST 2024, time=2024-03-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2191575, encodeId=455e21915e55e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基础研究 经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:47:39 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2185219, encodeId=922b218521981, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Feb 01 14:16:21 CST 2024, time=2024-02-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183905, encodeId=34682183905f8, content=偏重的研究方向：肿瘤 经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Jan 25 16:12:06 CST 2024, time=2024-01-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1237643, encodeId=3dfd123e643cd, content=审稿速度:1.0 偏重的研究方向：胃癌;生信 经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Aug 09 17:19:39 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160993, encodeId=8fa32160993d6, content=有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Oct 05 08:02:49 CST 2023, time=2023-10-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2174798, encodeId=c25321e4798cc, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信加细胞功能实验 经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！ Submission is in publishing and rights 12 Dec 2023 Peer review Submission status Date Submission accepted 12 Dec 2023 Submission under peer review 06 Dec 2023 Submission passed technical check 06 Dec 2023 Revision received 03 Dec 2023 Submission under peer review 15 Nov 2023 Submission passed technical check 15 Nov 2023 Revision received 14 Nov 2023 Submission under peer review 05 Sep 2023 Submission passed technical check 05 Sep 2023 Revision received 04 Sep 2023 Submission under peer review 05 Aug 2023 Technical check Submission status Date Submission passed technical check 05 Aug 2023 Submission is under technical check 04 Aug 2023 Submission received Submission status Date Submission received 04 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=究极奥美拉唑, createdTime=Wed Dec 13 20:39:35 CST 2023, time=2023-12-13, status=1, ipAttribution=广西)]

2024-02-01 ms6000001259041667 来自北京

审稿速度:1.0
偏重的研究方向：肿瘤
经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊

19 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194218, encodeId=432a2194218a4, content=偏重的研究方向：临床肿瘤基础研究 经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230522/2d526ad49c9d4a238ea5253f6b93381d/a6944e09a4254363923c04ea9167b795.jpg, createdBy=e0d95253850, createdName=lmzzzh, createdTime=Wed Mar 20 09:43:23 CST 2024, time=2024-03-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2191575, encodeId=455e21915e55e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基础研究 经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:47:39 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2185219, encodeId=922b218521981, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Feb 01 14:16:21 CST 2024, time=2024-02-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183905, encodeId=34682183905f8, content=偏重的研究方向：肿瘤 经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Jan 25 16:12:06 CST 2024, time=2024-01-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1237643, encodeId=3dfd123e643cd, content=审稿速度:1.0 偏重的研究方向：胃癌;生信 经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Aug 09 17:19:39 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160993, encodeId=8fa32160993d6, content=有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Oct 05 08:02:49 CST 2023, time=2023-10-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2174798, encodeId=c25321e4798cc, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信加细胞功能实验 经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！ Submission is in publishing and rights 12 Dec 2023 Peer review Submission status Date Submission accepted 12 Dec 2023 Submission under peer review 06 Dec 2023 Submission passed technical check 06 Dec 2023 Revision received 03 Dec 2023 Submission under peer review 15 Nov 2023 Submission passed technical check 15 Nov 2023 Revision received 14 Nov 2023 Submission under peer review 05 Sep 2023 Submission passed technical check 05 Sep 2023 Revision received 04 Sep 2023 Submission under peer review 05 Aug 2023 Technical check Submission status Date Submission passed technical check 05 Aug 2023 Submission is under technical check 04 Aug 2023 Submission received Submission status Date Submission received 04 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=究极奥美拉唑, createdTime=Wed Dec 13 20:39:35 CST 2023, time=2023-12-13, status=1, ipAttribution=广西)]

2024-01-25 ms6000001259041667 来自北京

偏重的研究方向：肿瘤
经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊

30 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194218, encodeId=432a2194218a4, content=偏重的研究方向：临床肿瘤基础研究 经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230522/2d526ad49c9d4a238ea5253f6b93381d/a6944e09a4254363923c04ea9167b795.jpg, createdBy=e0d95253850, createdName=lmzzzh, createdTime=Wed Mar 20 09:43:23 CST 2024, time=2024-03-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2191575, encodeId=455e21915e55e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基础研究 经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:47:39 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2185219, encodeId=922b218521981, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Feb 01 14:16:21 CST 2024, time=2024-02-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183905, encodeId=34682183905f8, content=偏重的研究方向：肿瘤 经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Jan 25 16:12:06 CST 2024, time=2024-01-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1237643, encodeId=3dfd123e643cd, content=审稿速度:1.0 偏重的研究方向：胃癌;生信 经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Aug 09 17:19:39 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160993, encodeId=8fa32160993d6, content=有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Oct 05 08:02:49 CST 2023, time=2023-10-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2174798, encodeId=c25321e4798cc, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信加细胞功能实验 经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！ Submission is in publishing and rights 12 Dec 2023 Peer review Submission status Date Submission accepted 12 Dec 2023 Submission under peer review 06 Dec 2023 Submission passed technical check 06 Dec 2023 Revision received 03 Dec 2023 Submission under peer review 15 Nov 2023 Submission passed technical check 15 Nov 2023 Revision received 14 Nov 2023 Submission under peer review 05 Sep 2023 Submission passed technical check 05 Sep 2023 Revision received 04 Sep 2023 Submission under peer review 05 Aug 2023 Technical check Submission status Date Submission passed technical check 05 Aug 2023 Submission is under technical check 04 Aug 2023 Submission received Submission status Date Submission received 04 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=究极奥美拉唑, createdTime=Wed Dec 13 20:39:35 CST 2023, time=2023-12-13, status=1, ipAttribution=广西)]

2022-08-09 ms2000000713462597

审稿速度:1.0
偏重的研究方向：胃癌;生信
经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。

40 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194218, encodeId=432a2194218a4, content=偏重的研究方向：临床肿瘤基础研究 经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230522/2d526ad49c9d4a238ea5253f6b93381d/a6944e09a4254363923c04ea9167b795.jpg, createdBy=e0d95253850, createdName=lmzzzh, createdTime=Wed Mar 20 09:43:23 CST 2024, time=2024-03-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2191575, encodeId=455e21915e55e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基础研究 经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:47:39 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2185219, encodeId=922b218521981, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Feb 01 14:16:21 CST 2024, time=2024-02-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183905, encodeId=34682183905f8, content=偏重的研究方向：肿瘤 经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Jan 25 16:12:06 CST 2024, time=2024-01-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1237643, encodeId=3dfd123e643cd, content=审稿速度:1.0 偏重的研究方向：胃癌;生信 经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Aug 09 17:19:39 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160993, encodeId=8fa32160993d6, content=有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Oct 05 08:02:49 CST 2023, time=2023-10-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2174798, encodeId=c25321e4798cc, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信加细胞功能实验 经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！ Submission is in publishing and rights 12 Dec 2023 Peer review Submission status Date Submission accepted 12 Dec 2023 Submission under peer review 06 Dec 2023 Submission passed technical check 06 Dec 2023 Revision received 03 Dec 2023 Submission under peer review 15 Nov 2023 Submission passed technical check 15 Nov 2023 Revision received 14 Nov 2023 Submission under peer review 05 Sep 2023 Submission passed technical check 05 Sep 2023 Revision received 04 Sep 2023 Submission under peer review 05 Aug 2023 Technical check Submission status Date Submission passed technical check 05 Aug 2023 Submission is under technical check 04 Aug 2023 Submission received Submission status Date Submission received 04 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=究极奥美拉唑, createdTime=Wed Dec 13 20:39:35 CST 2023, time=2023-12-13, status=1, ipAttribution=广西)]

2023-10-05 ms8000000524560535 来自重庆

有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受

21 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191590, encodeId=dce6219159003, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：还是比较快的 Submission is in publishing and rights 05 Mar 2024 Peer review Submission status Date Submission accepted 05 Mar 2024 Submission under peer review 16 Feb 2024 Submission passed technical check 16 Feb 2024 Revision received 15 Feb 2024 Submission under peer review 11 Jan 2024 Technical check Submission status Date Submission passed technical check 11 Jan 2024 Submission is under technical check 10 Jan 2024 Submission received Submission status Date Submission received 10 Jan 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e8382356, createdName=ms5000001486959246, createdTime=Wed Mar 06 21:41:34 CST 2024, time=2024-03-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192970, encodeId=095d21929e092, content=偏重的研究方向：肿瘤临床;肿瘤 经验分享：大神们，The eidtors' decision can take several weeks as they may consult peer reviews.这种状态是审了还是没审啊，2周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Wed Mar 13 15:01:47 CST 2024, time=2024-03-13, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194218, encodeId=432a2194218a4, content=偏重的研究方向：临床肿瘤基础研究 经验分享：有没有知道的大佬们，临床肿瘤基础研究这个杂志收不收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230522/2d526ad49c9d4a238ea5253f6b93381d/a6944e09a4254363923c04ea9167b795.jpg, createdBy=e0d95253850, createdName=lmzzzh, createdTime=Wed Mar 20 09:43:23 CST 2024, time=2024-03-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2191575, encodeId=455e21915e55e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;基础研究 经验分享：家人们，还没有修过变成这样了，The editors' decision can take several weeks as they may consult peer reviewers.是不是凉了啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733b8201136, createdName=ms8000000280791103, createdTime=Wed Mar 06 19:47:39 CST 2024, time=2024-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2185219, encodeId=922b218521981, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：邀请20个审稿人 15天拒稿没理由也不知道审没审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Feb 01 14:16:21 CST 2024, time=2024-02-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183905, encodeId=34682183905f8, content=偏重的研究方向：肿瘤 经验分享：1月16投的一天就过了技术审查现在显示peer review 但是我看下面详情写着正在找合适的编辑管理文章所以文章现在是审呢还是还没有编辑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c389144074, createdName=ms6000001259041667, createdTime=Thu Jan 25 16:12:06 CST 2024, time=2024-01-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1237643, encodeId=3dfd123e643cd, content=审稿速度:1.0 偏重的研究方向：胃癌;生信 经验分享：Journal of Cancer Research and Clinical Oncology，大部分为纯生信内容，几天就被拒了，优先级不够，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Aug 09 17:19:39 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160993, encodeId=8fa32160993d6, content=有兄弟出现这种情况吗，技术审查通过后，两个审稿人接受，时间频繁变动，最后三个审稿人接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Oct 05 08:02:49 CST 2023, time=2023-10-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2174798, encodeId=c25321e4798cc, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信加细胞功能实验 经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！ Submission is in publishing and rights 12 Dec 2023 Peer review Submission status Date Submission accepted 12 Dec 2023 Submission under peer review 06 Dec 2023 Submission passed technical check 06 Dec 2023 Revision received 03 Dec 2023 Submission under peer review 15 Nov 2023 Submission passed technical check 15 Nov 2023 Revision received 14 Nov 2023 Submission under peer review 05 Sep 2023 Submission passed technical check 05 Sep 2023 Revision received 04 Sep 2023 Submission under peer review 05 Aug 2023 Technical check Submission status Date Submission passed technical check 05 Aug 2023 Submission is under technical check 04 Aug 2023 Submission received Submission status Date Submission received 04 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=究极奥美拉唑, createdTime=Wed Dec 13 20:39:35 CST 2023, time=2023-12-13, status=1, ipAttribution=广西)]

2023-12-13 究极奥美拉唑来自广西

审稿速度:6.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;生信加细胞功能实验
经验分享：历时四个月多月，除去期刊改革耽误2个月左右，整体还算比较顺利，希望各位朋友多中文章！！！
Submission is in publishing and rights
12 Dec 2023
Peer review
Submission status Date
Submission accepted
12 Dec 2023
Submission under peer review
06 Dec 2023
Submission passed technical check
06 Dec 2023
Revision received
03 Dec 2023
Submission under peer review
15 Nov 2023
Submission passed technical check
15 Nov 2023
Revision received
14 Nov 2023
Submission under peer review
05 Sep 2023
Submission passed technical check
05 Sep 2023
Revision received
04 Sep 2023
Submission under peer review
05 Aug 2023
Technical check
Submission status Date
Submission passed technical check
05 Aug 2023
Submission is under technical check
04 Aug 2023
Submission received
Submission status Date
Submission received
04 Aug 2023

25 12

展开12条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务